Affiliations 

  • 1 a Faculty of Medicine and Defence Health , National Defence University of Malaysia , Kuala Lumpur , Malaysia
  • 2 b Scientific Centre for Expertise of Medical Application Products , Moscow , Russia
  • 3 c iPROMISE, Non-Destructive Biomedical and Pharmaceutical Research Centre, Universiti Teknologi MARA , Selangor , Malaysia
  • 4 d Ophthalmic Microsurgery Department, International Medical Center Oftalmika , Kharkiv , Ukraine , and
  • 5 e Institute of Pharmaceutical Technology, Goethe University , Frankfurt , Germany
Drug Deliv, 2016 Jul 16;23(9):3520-3528.
PMID: 27278330 DOI: 10.1080/10717544.2016.1199609

Abstract

Currently, traumatic brain injury (TBI) is the leading cause of death or disabilities in young individuals worldwide. The multi-complexity of its pathogenesis as well as impermeability of the blood-brain barrier (BBB) makes the drug choice and delivery very challenging. The brain-derived neurotrophic factor (BDNF) regulates neuronal plasticity, neuronal cell growth, proliferation, cell survival and long-term memory. However, its short half-life and low BBB permeability are the main hurdles to be an effective therapeutic for TBI. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles coated by surfactant can enable the delivery of a variety of molecules across the BBB by receptor-mediated transcytosis. This study examines the ability of PLGA nanoparticles coated with poloxamer 188 (PX) to deliver BDNF into the brain and neuroprotective effects of BNDF in mice with TBI. C57bl/6 mice were subjected to weight-drop closed head injuries under anesthesia. Using enzyme-linked immunosorbent assay, we demonstrated that the intravenous (IV) injection of nanoparticle-bound BDNF coated by PX (NP-BDNF-PX) significantly increased BDNF levels in the brain of sham-operated mice (p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.